Ticagrelor monotherapy after short duration of dual antiplatelet therapy compared to continued dual antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary interventions: an updated meta-analysis

被引:0
|
作者
Mansuri, Zeeshan [1 ]
Ashraf, Hadiah [2 ]
Taikadan, Thahsin [3 ]
Rajith, Gokul [4 ]
Ayesha, Ayesha [5 ]
Fatima, Urooj [6 ]
Erzinger, Gabriel [7 ]
机构
[1] GCS Med Coll & Res Ctr, Dept Cardiol, Opp DRM Off,Naroda Rd, Ahmadabad 380025, Gujarat, India
[2] Rawalpindi Med Univ, Rawalpindi, Pakistan
[3] Calicut Med Coll, Kozhikode, India
[4] All India Inst Med Sci, Gauhati, India
[5] Shifa Coll Med, Islamabad, Pakistan
[6] Jinnah Sindh Med Univ, Karachi, Pakistan
[7] Univ Joinville Reg UNIVILLE, Joinville, Brazil
关键词
dual anti-platelet therapy; percutaneous coronary intervention; ticagrelor; ASPIRIN;
D O I
10.1097/MCA.0000000000001417
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The optimum duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients with acute coronary syndromes (ACS) remains controversial. Ticagrelor monotherapy after short duration of DAPT (1-3 months) is a subject of research. We conducted an updated systematic review and meta-analysis comparing the ticagrelor monotherapy with continued DAPT after short duration of DAPT in patients with ACS undergoing PCI. Methods PubMed, Embase, and Cochrane databases were searched for studies comparing ticagrelor monotherapy to DAPT after PCI and reported the outcomes of major adverse cardiovascular and cerebrovascular events (MACCE); net adverse clinical events (NACE); myocardial infarction (MI); major bleeding; death from any cause; definite or probable stent thrombosis; and target vessel revascularization (TVR). Data were extracted from published reports and quality assessment was performed per Cochrane recommendations. Statistical analysis was performed using Review Manager (Cochrane collaboration). Heterogeneity was examined with I-2 test. Results Of 3,208 results, five studies with 21,407 patients were included of which 50% received ticagrelor monotherapy. Studies had reported follow up of 12 months. Major bleeding [hazard ratio 0.47; 95% confidence interval (CI), 0.37-0.61; P < 0.001], NACE (hazard ratio 0.71; 95% CI, 0.56-0.90; P = 0.005), and all-cause death (hazard ratio 0.76; 95% CI, 0.59-0.98; P = 0.04) were significantly less with ticagrelor monotherapy. Other outcomes were comparable in both groups. Conclusion In patients with ACS undergoing PCI, ticagrelor monotherapy reduces major bleeding, NACE and all-cause death as compared to continued DAPT for 12 months. Major ischemic outcomes were similar. Ticagrelor monotherapy is the way forward after short duration of DAPT after PCI in ACS.
引用
收藏
页码:590 / 597
页数:8
相关论文
共 50 条
  • [41] Dual antiplatelet therapy after acute coronary syndromes: no time for a CHANGE
    Capodanno, Davide
    EUROINTERVENTION, 2017, 13 (10) : 1133 - 1135
  • [42] Duration of dual antiplatelet therapy after coronary stenting
    Briasoulis, Alexandros
    Palla, Mohan
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 222 : 1064 - 1067
  • [43] Prasugrel as Antiplatelet Therapy in Patients With Acute Coronary Syndromes or Undergoing Percutaneous Coronary Intervention
    Fletcher, Barbara
    Thalinger, Karen K.
    CRITICAL CARE NURSE, 2010, 30 (05) : 45 - 54
  • [44] Dual Antiplatelet Therapy Dilemmas: Duration and Choice of Antiplatelets in Acute Coronary Syndromes
    Matthew Tomey
    Roxana Mehran
    Current Cardiology Reports, 2013, 15
  • [45] Duration of Dual Antiplatelet Therapy After Coronary Stenting
    Siasos, Gerasimos
    Mourouzis, Konstantinos
    Oikonomou, Evangelos
    Vavuranakis, Manolis
    Vogiatzi, Georgia
    Briasoulis, Alexandros
    Papageorgiou, Nikolaos
    Papaioannou, Theodore G.
    Zografos, Thodoris
    Papapanagiotou, Angeliki
    Papavassiliou, Athanasios G.
    Stefanadis, Christodoulos
    Tousoulis, Dimitris
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (29) : 4583 - 4595
  • [46] Dual Antiplatelet Therapy Dilemmas: Duration and Choice of Antiplatelets in Acute Coronary Syndromes
    Tomey, Matthew
    Mehran, Roxana
    CURRENT CARDIOLOGY REPORTS, 2013, 15 (10)
  • [47] Walking the Line with Ticagrelor: Meta-Analysis Comparing the Safety and Efficacy of Ticagrelor Monotherapy after a Short Course of Ticagrelor-Based Dual Antiplatelet Therapy versus Standard Therapy in Complex Percutaneous Coronary Intervention
    Condello, Francesco
    Sturla, Matteo
    Terzi, Riccardo
    Polimeni, Alberto
    Stefanini, Giulio G.
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (23)
  • [48] Ticagrelor monotherapy after a short course of dual antiplatelet therapy with ticagrelor plus aspirin following percutaneous coronary intervention in patients with versus without diabetes mellitus: a meta-analysis of randomized trials
    Ning, Chen
    Ling, Fang
    Liu, Deyi
    Zhi, Zhang
    BMC CARDIOVASCULAR DISORDERS, 2024, 24 (01)
  • [49] Ticagrelor monotherapy after a short course of dual antiplatelet therapy with ticagrelor plus aspirin following percutaneous coronary intervention in patients with versus without diabetes mellitus: a meta-analysis of randomized trials
    Chen Ning
    Fang Ling
    Deyi Liu
    Zhang Zhi
    BMC Cardiovascular Disorders, 24
  • [50] Short dual antiplatelet therapy in patients with high bleeding risk undergoing percutaneous coronary intervention: a systematic review and meta-analysis
    Zhang, Junyan
    Chen, Zhongxiu
    Li, Chen
    Wang, Duolao
    He, Siyu
    Luo, Chaoyu
    Luo, Fangbo
    He, Yong
    CORONARY ARTERY DISEASE, 2022, 33 (07) : 580 - 589